Timothy Morris, MD

Director, Pulmonary Clinical Programs UCSD Medical Center - Hillcrest Associate Professor of Medicine Medical Director, Respiratory Care Medical Director, Pulmonary Function Laboratory

President, California Thoracic Society 2003-2004

Distinguished Scholar in Thrombosis, American College of Chest Physicians 2003-2006 (inaugural awardee)

Chairman, Department of Medicine Continuous Quality Improvement Committee Department of Medicine. Housestaff Teaching Awards 1995, 1996, 1997, 1998, 1999, 2001, 2002

CLINICAL INTERESTS:

1. General pulmonary medicine
2. Acute pulmonary thromboembolic disease
3. Critical Care

INVESTIGATIVE INTERESTS:

Acute pulmonary thromboembolic disease

SELECTED PUBLICATIONS:

1. Morris TA, Auger WR, Ysrael MZ, Olson LK, Channick RN, Fedullo PF, Moser KM. Parenchymal scarring is associated with restrictive spirometric defects in patients with chronic thromboembolic pulmonary hypertension. Chest 1966;110:399-403.
2. Morris TA, Ysrael MZ, Olson LK, Auger WR, Fedullo PF, Moser KM. Restrictive spirometric defect in patients with chronic pulmonary thromboembolic hypertension. Chest 1992;102(2):120s.
3. Morris TA, March JJ, Konopka RG, Pedersen CA, Chiles PG, Moser KM. Antifibrin monoclonal antibodies detect deep vein thrombosis in a canine model. Chest 1993;104(5):24s.
4. Yi ES, Auger WR, Friedman PJ, Morris TA, Shin SS. Intravascular bronchoalveolar tumor of the lung presenting as pulmonary thromboembolic disease and pulmonary hypertension. Arch Pathol Lab Med 1995;119:225-60.
5. Morris TA. Pulmonary complications in burn patients (previously "inhalation injury"). In Manual of Clinical Problems in Pulmonary Medicine, 4th Edition. Bordow RA, Moser KM, editors. Boston: Little, Brown & Company. pp. 376-81, 1996.
6. Morris TA. Histoplasmosis. In Manual of Clinical Problems in Pulmonary Medicine, 4th Edition. Bordow RA, Moser KM, editors. Boston: Little, Brown & Company. pp. 156-60, 1996.
7. Morris TA, Marsh JJ, Konopka R, Pedersen CA, Chiles PG, Fagnani R, Hagan M, Moser KM. Antibodies against the fibrin-chain amino terminus detect active canine venous thrombi. Circulation 1997;96(9):3173-9.
8. Morris TA, Marsh JJ, Fagnani R, Hagan M, Moser KM. Degree of polymer organization decreases the binding of a monoclonal antibody raised against the -chain amino terminus of fibrin. Thromb Haemost 1997;77:704-9.
9. Morris TA, J.J.;Chiles, P.G.;Pedersen, C.A.;Konopka, R.G.;Gamst, A.C.; Loza, O. Embolization Itself Stimulates Thrombus Propagation in Pulmonary Embolism. Am J Physiol Heart Circ Physiol. 2004;in press.
10. Morris TA, Marsh JJ, Chiles PG, Konopka RG, Pedersen CA, Schmidt PF, Gerometta M. Single Photon Emission Computed Tomography of Pulmonary Emboli and Venous Thrombi Using Anti-D-dimer. Am J Respir Crit Care Med. 2004.in press.
11. Morris TA, Marsh JJ, Burrows CM, Chiles PG, Konopka RG, Pedersen CA. Urine and plasma levels of fibrinopeptide B in patients with deep vein thrombosis and pulmonary embolism. Thromb Res. 2003;110:159-65.
12. Morris TA. Heparin and low molecular weight heparin: background and pharmacology. Clin Chest Med JID - 7907612. 2003;24:39-47.
13. Morris TA. Diagnostic Test for Thrombotic or Thromboembolic Disease. In: Regents of the University of California; 2003.
14. Morris TA. Thromboembolic Disease - Epidemiology, Natural History and Diagnosis. In: Bordow RA, Ries AL, Morris TA, eds. Manual of Clinical Problems in Pulmonary Medicine. 5 ed. Philadelphia: Lippincott Williams & Wilkins; 2001:321-328.
15. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest JID - 0231335. 2001;119:176S-193S.
16. Yi ES, Kim H, Ahn H, Strother J, Morris T, Masliah E, Hansen LA, Park K, Friedman PJ. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. American Journal of Respiratory and Critical Care Medicine. 2000;162:1577-1586.
17. Morris TA, Marsh JJ, Konopka R, Pedersen CA, Chiles PG. Anti-thrombotic efficacies of enoxaparin, dalteparin, and unfractionated eparin in venous thrombo-embolism. Thromb Res JID - 0326377. 2000;100:185-194
18. Tapson VF, Carroll BA, Davidson BL, Elliott CG, Fedullo PF, Hales CA, Hull RD, Hyers TM, Leeper KJ, Morris TA, Moser KM, Raskob GE, Shure D, Sostman HD, Taylor T. The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. American Thoracic Society. American Journal of Respiratory and Critical Care Medicine. 1999;160:1043-1066.
19. Kim H, Yung GL, Marsh JJ, Konopka RG, Pedersen CA, Chiles PG, Morris TA, Channick RN. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. European Respiratory Journal. 2000;15:640-648.
20. Kim H, Yung GL, Morris TA, Marsh JJ, Chiles P, Pedersen C, Konopka R, Channick R. Endothelin Antagonism Inhibits Pulmonary Vascular Remodeling In Canine Chronic Pulmonary Embolism. American Journal of Respiratory and Critical Care Medicine. 1999;159:566.
21. Kim H, Yung GL, Marsh JJ, Konopka RG, Pedersen CA, Chiles PG, Morris TA, Channick RN. Pulmonary vascular remodeling distal to pulmonary artery ligation is accompanied by upregulation of endothelin receptors and nitric oxide synthase. Experimental Lung Research. 2000;26:287-301.
22. Morris TA, Marsh JJ, Konopka R, Pedersen CA, Chiles PG, Fagnani R, Hagan M, Moser KM. Antibodies against the fibrin beta-chain amino-terminus detect active canine venous thrombi. Circulation. 1997;96:3173-3179.
23. Morris TA, Marsh JJ, Fagnani R, Hagan M, Moser KM. Degree of polymer organization decreases the binding of a monoclonal antibody raised against the beta-chain amino terminus of fibrin. Thrombosis and Haemostasis. 1997;77:704-709.
24. Morris TA, Auger WR, Ysrael MZ, Olson LK, Channick RN, Fedullo PF, Moser KM. Parenchymal scarring is associated with restrictive spirometric defects in patients with chronic thromboembolic pulmonary hypertension. Chest. 1996;110:399-403.